These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10766024)

  • 1. Generation of cellular immune responses to antigenic tumor peptides.
    Pietersz GA; Apostolopoulos V; McKenzie IF
    Cell Mol Life Sci; 2000 Feb; 57(2):290-310. PubMed ID: 10766024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
    Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
    J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
    Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
    J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
    Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
    J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
    Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
    J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
    Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
    Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).
    Koumantou D; Barnea E; Martin-Esteban A; Maben Z; Papakyriakou A; Mpakali A; Kokkala P; Pratsinis H; Georgiadis D; Stern LJ; Admon A; Stratikos E
    Cancer Immunol Immunother; 2019 Aug; 68(8):1245-1261. PubMed ID: 31222486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
    Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
    Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
    Wang RF
    Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
    Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
    Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
    Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
    Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.